Apr 10 |
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
|
Apr 10 |
Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate
|
Apr 8 |
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
|
Apr 4 |
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
|
Apr 3 |
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
|
Apr 2 |
Recursion to Participate in Upcoming Investor Conference
|
Apr 1 |
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy
|
Mar 27 |
Cathie Wood's Ark Invest Continues To Double Down On Moderna, Sells Nvidia Shares
|
Mar 26 |
Recursion Publishes Annual Environmental, Social and Governance Report
|
Mar 20 |
Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)
|